Overview

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

Status:
Active, not recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if lenalidomide when given along with rituximab can help to control the disease and also increase the length of your response (complete or partial response) compared to the standard of care rituximab chemotherapy treatment.

Phase:

Phase 3

Details

Lead Sponsor:

The Lymphoma Academic Research Organisation

Collaborator:

Celgene Corporation

Treatments:

Bendamustine Hydrochloride
Lenalidomide
Rituximab
Thalidomide